Avita Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCEL research report →
About the company
AVITA Medical, Inc. , together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
- CEO
- Cary G. Vance
- IPO
- 2012
- Employees
- 232
- HQ
- Valencia, CA, US
Price Chart
- Market Cap
- $125.71M
- P/E
- -0.14
- P/S
- 1.74
- P/B
- -0.07
- EV/EBITDA
- -4.39
- Div Yield
- 0.00%
- Gross Margin
- 81.36%
- Op Margin
- -54.61%
- Net Margin
- -62.67%
- ROE
- 305.45%
- ROIC
- -127.38%
- Revenue
- $71.61M · 11.45%
- Net Income
- $-48,587,000 · 21.44%
- EPS
- $-1.74 · 27.20%
- Op Income
- $-42,534,000
- FCF YoY
- 43.48%
- 52W High
- $7.12
- 52W Low
- $3.22
- 50D MA
- $4.25
- 200D MA
- $4.25
- Beta
- 1.86
- Avg Volume
- 290.51K
Get TickerSpark's AI analysis on RCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | O'Toole David D | other | 2,000 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,200 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 3, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 3, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jan 20, 26 | McNamara Robert | other | 22,214 |
| Jan 20, 26 | McNamara Robert | other | 16,133 |
| Jan 20, 26 | Woody Joseph Fralin | other | 22,214 |
| Jan 5, 26 | Woody Joseph Fralin | other | 40,547 |
Our RCEL coverage
Recent articles, reports, and earnings notes.
No research on RCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCEL report →Similar companies
Peers in the same neighborhood.